EDBu/OHPH/TCa
Combination of
Estradiol dibutyrateEstrogen
Hydroxyprogesterone heptanoateProgestogen
Testosterone cyclohexylpropionateAndrogen; Anabolic steroid
Clinical data
Trade namesTriormon Depositum
Other namesEDBu/OHPH/TCa
Routes of
administration		Intramuscular injection

Estradiol dibutyrate/hydroxyprogesterone heptanoate/testosterone caproate (EDBu/OHPH/TCa), sold under the brand name Triormon Depositum, is an injectable combination medication of estradiol dibutyrate (EDBu), an estrogen, hydroxyprogesterone heptanoate (OHPH), a progestogen, and testosterone caproate (TCa), an androgen/anabolic steroid, which was used in the treatment of menopausal symptoms in women.[1] It contained 3 mg EDBu, 30 mg OHPH, and 50 mg TCa in oil solution and was administered by intramuscular injection.[1] The medication was developed by 1957.[1] It is no longer available.[2][3]

See also

References

  1. 1 2 3 Ermiglia G, Valli P (May 1957). "Studio sul triormon depositum nella sindrome climaterica; curve di eliminazione dei cataboliti e durata dell'effetto terapeutico" [Study of tribormone depositum in the climacteric syndrome; catabolite elimination curves and duration of the therapeutic effect]. Quaderni di Clinica Ostetrica e Ginecologica (in Italian). 12 (5): 284–93. ISSN 0033-491X. PMID 13465973. Triormon depositum (estradiol dibutyrate 3, testosterone caprylate 50, and hydroxyprogesterone heptanoate 30 mg.), administered in castor oil-benzyl benzoate soln. or polyvinylpyrrolidone suspension to 21 women in climacteric, was followed by estradiol, pregnanediol, and 17-keto steroid urinary curves, most with a peak at the 4th day, and approaching starting values at the 8-10th day. The therapeutic efficacy of the drug was satisfactory.
  2. ↑ "Home". micromedexsolutions.com.
  3. ↑


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.